Trade

with

Anika Therapeutics Inc
(NASDAQ: ANIK)
AdChoices
37.72
-0.05
-0.13%
After Hours :
37.72
0.00
0.00%

Open

37.85

Previous Close

37.77

Volume (Avg)

188.11k (279.05k)

Day's Range

37.60-38.78

52Wk Range

26.16-52.49

Market Cap.

546.43M

Dividend Rate ( Yield )

-

Beta

1.77

Shares Outstanding

14.49M

P/E Ratio (EPS)

16.08 (2.35)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 75.08M

    • Net Income

    • 20.57M

    • Market Cap.

    • 546.43M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 36.20

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.77

    • Forward P/E

    • 21.19

    • Price/Sales

    • 5.82

    • Price/Book Value

    • 3.36

    • Price/Cash flow

    • 16.16

      • EBITDA

      • 37.38M

      • Return on Capital %

      • 21.95

      • Return on Equity %

      • 25.51

      • Return on Assets %

      • 21.95

      • Book Value/Share

      • 11.21

      • Shares Outstanding

      • 14.49M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 51.50

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 1.78

        • Cashflow Estimate

        • 1.96

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 26.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 75.00

          • 17.04

          • Net Income

            Q/Q (last year)

          • 57.80

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 15.98

          • 63.43

          • Net Income

            5-Year Annual Average

          • 41.50

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 78.54

            • 82.75

            • Pre-Tax Margin

            • 57.63

            • 39.38

            • Net Profit Margin

            • 36.20

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 62.20

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 23.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 14.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 16.32

              • 2.92

              • Quick Ratio

              • 14.22

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.10

              • 2.21

              • Book Value/Share

              • 11.21

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 16.10

                • 277.78

                • P/E Ratio 5-Year High

                • 22.38

                • 634.30

                • P/E Ratio 5-Year Low

                • 2.06

                • 124.82

                • Price/Sales Ratio

                • 5.83

                • 9.35

                • Price/Book Value

                • 3.37

                • 8.50

                • Price/Cash Flow Ratio

                • 16.16

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 25.51

                    (9.60)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 21.95

                    (7.10)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 25.51

                    (8.70)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 352.39k

                  • 117.08k

                  • Inventory Turnover

                  • 1.76

                  • 1.48

                  • Asset Turnover

                  • 0.61

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  32.61M
                  Operating Margin
                  43.43
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  16.16
                  Ownership

                  Institutional Ownership

                  81.10%

                  Top 10 Institutions

                  38.70%

                  Mutual Fund Ownership

                  33.21%

                  Float

                  98.19%

                  5% / Insider Ownership

                  3.32%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    290,002

                  • 0.24

                  • 2.02

                  • Vanguard Total Stock Mkt Idx

                  •  

                    232,370

                  • 0.00

                  • 1.60

                  • iShares Russell 2000 (AU)

                  •  

                    224,100

                  • -1.02

                  • 1.56

                  • DFA US Small Cap Value II Portfolio

                  •  

                    194,619

                  • 0.00

                  • 1.32

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    170,098

                  • 0.00

                  • 1.15

                  • BlackRock Small Cap Growth Equity Port

                  •  

                    125,736

                  • 4.44

                  • 0.87

                  • iShares S&P Small-Cap 600 Growth

                  •  

                    122,809

                  • 0.00

                  • 0.86

                  • Vanguard Extended Market Index Fund

                  •  

                    117,017

                  • 6.75

                  • 0.81

                  • Gotham Absolute Return Fund

                  •  

                    104,867

                  • 166.85

                  • 0.71

                  • DFA U.S. Small Cap Portfolio

                  •  

                    104,772

                  • 0.00

                  • 0.71

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Dimensional Fund Advisors, Inc.

                  •  

                    951,130

                  • +2.22%

                  • 6.43

                  • BlackRock Fund Advisors

                  •  

                    691,614

                  • +3.44%

                  • 4.67

                  • Vanguard Group, Inc.

                  •  

                    547,501

                  • +16.06%

                  • 3.70

                  • Wellington Management Company, LLP

                  •  

                    389,332

                  • +23.35%

                  • 2.63

                  • Allianz Global Investors

                  •  

                    377,976

                  • -10.32%

                  • 2.55

                  • Renaissance Technologies Corp

                  •  

                    367,400

                  • -16.95%

                  • 2.48

                  • Bogle Investment Management L P

                  •  

                    284,393

                  • 0.00%

                  • 1.92

                  • State Street Corp

                  •  

                    280,061

                  • +3.99%

                  • 1.89

                  • Thompson, Siegel & Walmsley LLC

                  •  

                    263,622

                  • +32,852.75%

                  • 1.78

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Aggressive Growth

                  Style

                  Small Growth

                  Anika Therapeutics, Inc., was incorporated in 1992 as a Massachusetts company. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluron...moreic acid, or HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its biophysical and biochemical properties, HA performs physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. The Company through tis subsidiary has over 20 products currently commercialized, mainly in Europe. These products are made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an au...moretocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. Its Orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its Dermal products consist of advanced wound care products, based on the HYAFF technology, and aesthetic dermal fillers. The HYAFF technology offers products for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents, advanced therapies to aid healing and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products include AMVISC and AMVISC Plus product line, STAARVISC-IITM, Optivisc, AnikaVisc and AnikaVisc Plus which are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. Hyalobarrier is a clinically proven post-operative adhesion barrier for use in the abdomino-pelvic area. The product is currently commercialized in Europe, the Middle East and certain Asian countries through a distribution network, but is not approved in the U.S. INCERT, approved for sale in Europe, Turkey, and Malaysia. It is chemically modified, cross-linked HA product for the prevention of spinal post-surgical adhesions. The Company along with its subsidiary offers products used in connection with the treatment of ENT disorders. The products are Merogel, a woven fleece nasal packing, and Merogel Injectable, a thick, viscous hydrogel composed of cross-linked hyaluronic acid—a biocompatible agent that creates a moist wound-healing environment. Its research, including clinical research, development, manufacture, and marketing of products are subject to regulation by numerous governmental authorities in the U.S. and other countries.lessless

                  Key People

                  Dr. Charles H. Sherwood,PhD

                  CEO/Director/President

                  Ms. Sylvia Cheung

                  CFO/Chief Accounting Officer/Secretary/Treasurer

                  Steven E. Wheeler

                  Director

                  John C. Moran

                  Director

                  Raymond J. Land

                  Director

                  • Anika Therapeutics Inc

                  • 32 Wiggins Avenue

                  • Bedford, MA 01730

                  • USA.Map

                  • Phone: +1 781 457-9000

                  • Fax: +1 781 305-9720

                  • anikatherapeutics.com

                  Incorporated

                  1992

                  Employees

                  102

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: